LEADER 03716nam 2200601Ia 450 001 9910140756503321 005 20170815170233.0 010 $a3-527-63212-3 010 $a1-282-78383-1 010 $a9786612783838 010 $a3-527-63003-1 010 $a3-527-63004-X 035 $a(CKB)2670000000047583 035 $a(EBL)584980 035 $a(OCoLC)670411405 035 $a(SSID)ssj0000456796 035 $a(PQKBManifestationID)11303031 035 $a(PQKBTitleCode)TC0000456796 035 $a(PQKBWorkID)10409606 035 $a(PQKB)10336058 035 $a(MiAaPQ)EBC584980 035 $a(EXLCZ)992670000000047583 100 $a20100303d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAnalogue-based drug discovery II$b[electronic resource] /$fedited by Janos Fischer and C. Robin Ganellin 210 $aWeinheim $cWiley-VCH$dc2010 215 $a1 online resource (566 p.) 300 $aDescription based upon print version of record. 311 $a3-527-32549-2 320 $aIncludes bibliographical references and index. 327 $aAnalogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs 327 $a9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 327 $a18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index 330 $aBorn out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development.Of interest 606 $aDrug development 606 $aDrugs$xDesign 608 $aElectronic books. 615 0$aDrug development. 615 0$aDrugs$xDesign. 676 $a615.19 701 $aFischer$b Ja?nos$0881301 701 $aGanellin$b C. R$g(C. Robin)$0881302 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910140756503321 996 $aAnalogue-based drug discovery II$92075967 997 $aUNINA